AndroGel Storage, Stability & Shelf Life: Complete Clinical Guide

AndroGel is a brand-name transdermal gel containing the hormone testosterone, available in 1% and 1.62% strengths, and classified as a Schedule III controlled substance in the United States. It is FDA-approved for testosterone replacement in men with confirmed hypogonadism. This article covers how it should be stored, what happens when storage conditions are not met, and how a storage problem can be distinguished from a genuine dosing or absorption problem. It does not cover dosing decisions for an individual patient, which should be made with a prescribing clinician.

The core answer

AndroGel's hydroalcoholic gel base, not the testosterone molecule itself, is the part most vulnerable to storage problems. Testosterone is a relatively stable steroid, but the ethanol and carbomer gel matrix that carries it across the skin barrier degrades with heat, freezing, and time. According to the FDA-approved product labeling, AndroGel should be kept at 68°F to 77°F (20°C to 25°C), away from open flame, and used before its printed expiration date; product that has been overheated, frozen, or expired may still look like normal gel while delivering meaningfully less testosterone than the labeled dose. (FDA-approved labeling and medication guide, see references.)

What AndroGel is and how it delivers testosterone

AndroGel works by passive transdermal diffusion. The gel base, which contains ethanol, carbomer, purified water, sodium hydroxide, and isopropyl myristate, temporarily loosens the lipid packing of the stratum corneum so that testosterone can move from the gel into the skin and then into dermal capillaries. Ethanol is the main penetration enhancer in this formulation. Manufacturer labeling describes peak serum concentrations occurring a few hours after application and steady-state levels developing over the first one to two days of daily use.

The 1.62% pump formulation is labeled to deliver a range of doses depending on the number of pump actuations, with the FDA-approved label reporting steady-state serum testosterone data for its studied doses. Exact concentration figures (for example, mean steady-state levels at specific actuation counts) are in the original 2011 approval labeling; because labels can be revised and dosing details matter clinically, anyone relying on a specific number for treatment decisions should confirm it against the current FDA label rather than this article.

Why storage temperature changes how much testosterone reaches the bloodstream

The clinically important mechanism is straightforward: ethanol is volatile, and it is the ingredient doing the work of opening the skin barrier. Heat accelerates its loss from a sealed packet or pump through evaporation and through gradual breakdown of the carbomer gel network. Cold, especially freezing, can disrupt that same carbomer network in a different way, causing the gel to separate into a watery, grainy, or uneven texture on thawing.

Neither of these changes is always visible to the eye at the point of use. A packet that spent a week in a hot car may look identical to one that was stored correctly, even though its penetration-enhancing capacity has already declined. This is the practical reason storage habits matter more for this drug than for many oral medications: the gel's job is not just to contain testosterone, it is to actively deliver it through skin, and that delivery mechanism is the more fragile part of the product.

Manufacturer stability testing for controlled-substance topical products of this kind is required under FDA regulations governing drug stability programs (21 CFR 211.166), which set the framework for the accelerated and long-term testing manufacturers use to justify a labeled shelf life. The expiration date on AndroGel reflects testing under recommended storage conditions, not under conditions of repeated heat exposure or freezing.

Recommended storage conditions

• Store at 68°F to 77°F (20°C to 25°C). Brief excursions to 59°F, 86°F (15°C, 30°C) are tolerated per USP controlled room temperature standards referenced in FDA storage guidance.
• Avoid a car, a sunlit windowsill, a shelf above a heater, or anywhere that regularly exceeds 86°F.
• Avoid freezing. Temperatures at or below 32°F (0°C) can disrupt the gel's polymer structure.
• Keep the product in its original packaging, which provides some protection from light. Testosterone and its formulation ingredients are sensitive to prolonged UV exposure, though sealed original packaging is generally adequate protection for normal home storage.
• Keep the pump cap tightly closed between uses, and keep unused foil packets sealed until use.
• Store away from any open flame, pilot light, or smoking area. The gel base is flammable until it dries on the skin.

What to do if the gel was exposed to heat or cold

If a packet or pump was left somewhere hot (a car in summer, a sunny counter) or was frozen, let it return to room temperature and inspect it before using it. Signs that suggest the product should be discarded rather than used include:

• visible water separation or a watery layer
• a grainy or gritty texture that was not there before
• an unusual color change
• a notably stronger or different alcohol odor than usual

If any of these are present, the product should not be used, and a replacement should be obtained. This is a judgment call based on general pharmaceutical stability principles and FDA guidance on physical product changes after storage excursions, not a formal assay a patient can perform at home. When in doubt, treat visibly changed product as unreliable rather than assuming partial potency.

Shelf life and expiration

AbbVie assigns a shelf life to AndroGel supported by real-time and accelerated stability testing, with the specific expiration printed on the carton, individual foil packet, and the base of the pump bottle. Manufacturers are required to demonstrate that labeled testosterone content stays within an accepted potency range through that date under recommended storage conditions. Using gel after that printed date is not recommended because there is no assurance the labeled concentration, or the vehicle's ability to deliver it, still holds.

Two distinct things can go wrong with expired or storage-damaged product: the testosterone concentration itself may have drifted down, or the vehicle's ability to carry testosterone across skin may have declined even if the testosterone concentration is intact. Either failure mode can produce the same clinical picture: lower serum testosterone than expected on an unchanged dose.

Flammability

AndroGel's ethanol content makes it flammable until it dries on the skin, generally within a few minutes under normal conditions. The FDA medication guide instructs patients to avoid smoking or being near open flame until the gel has dried. This has a storage implication as well as an application one: packets and pump bottles should be kept away from gas stoves, pilot lights, and other ignition sources, and any leaking packet near a flame source is a genuine hazard.

Secondary transfer to other people

AndroGel carries an FDA boxed warning about secondary exposure. Children who had skin contact with testosterone gel from a treated adult have developed signs of virilization, including premature pubic hair growth, genital enlargement, and advanced bone age. This is an application and hygiene issue more than a storage issue, but the two connect in one respect: gel that behaves abnormally because of heat exposure may spread more thinly or take longer to dry, which could extend the window during which transfer to another person's skin is possible. There is no published data quantifying this specific interaction; this is a plausible mechanical inference from how the gel dries, not an established finding, and should be treated as such.

Standard mitigation steps from FDA labeling apply regardless of storage history:

• Apply only to the sites specified on the label (shoulders and upper arms for the 1.62% strength; the abdomen is also permitted for the 1% strength).
• Wash hands with soap and water immediately after application.
• Let the site dry fully, then cover it with clothing.
• Wash the application site with soap and water before any skin-to-skin contact with a partner or child.

What the trial evidence does and does not establish about storage

Testosterone gel's efficacy for hypogonadism has been studied in placebo-controlled trials, including a large NIH-funded set of trials in older men with confirmed low testosterone (the Testosterone Trials), which reported improvements in sexual function and more modest effects on physical function outcomes with daily topical testosterone dosed to a target serum range. These trials establish that correctly manufactured, correctly stored testosterone gel used under controlled conditions can reliably raise serum testosterone into a target range. They do not directly test what happens to outcomes when gel is stored improperly in real-world conditions; that gap is inferred from pharmaceutical stability principles and the mechanism described above, not from a dedicated storage-outcomes trial. A clinical reviewer should verify the specific trial citation and findings against the primary publication before this section is finalized, since the identifying details in the original source draft could not be independently confirmed here.

Guideline bodies, including endocrine society clinical practice guidelines for male hypogonadism, generally define the condition using a low morning total testosterone confirmed on two occasions plus symptoms, and recommend checking serum testosterone roughly two weeks after starting or changing a topical testosterone dose, drawn several hours after application. Levels that remain unexpectedly low on an apparently adequate, consistently applied dose are one of the scenarios where a storage history should be reviewed before assuming the dose itself is inadequate. Readers and clinicians should confirm current numeric targets against the current published guideline rather than any single secondary summary, since these figures can be updated.

Testosterone therapy is also associated with an increase in hematocrit through stimulated red blood cell production, which is why monitoring hematocrit at baseline and periodically during treatment is standard practice; the exact average magnitude of increase varies across studies and should be verified against a primary source rather than treated as a fixed number.

Disposal

AndroGel is a Schedule III controlled substance. FDA disposal guidance recommends using an authorized drug take-back program as the preferred disposal method. If no take-back program is available, the FDA's general household disposal guidance for medicines suggests mixing gel contents with an undesirable substance such as coffee grounds or kitty litter, sealing it in a bag, and placing it in household trash, rather than flushing it or placing an open packet directly in the trash or recycling where a child or pet could contact it.

Evidence boundaries

Established: AndroGel's labeled storage range is 68°F to 77°F with defined tolerable excursions; the drug is flammable until dry; the FDA has issued a boxed warning for secondary transfer; the product carries a manufacturer-assigned expiration date supported by required stability testing; ethanol loss and carbomer disruption are recognized mechanisms of topical gel degradation.

Plausible but not directly proven for this product: that heat-damaged gel measurably increases secondary transfer risk through altered drying time; the precise magnitude of absorption loss from a specific temperature excursion in real-world use.

Not established from the material reviewed here: exact numeric prevalence of hypogonadism in the general population, exact steady-state serum concentration figures at each labeled dose, and exact trial citation details for the topical testosterone efficacy trials referenced above. These require confirmation against the current FDA label and the primary trial publication before being used in patient-facing numeric claims.

The AndroGel Storage Audit: a decision framework for unexpectedly low testosterone

Use this before assuming a stable AndroGel dose has stopped working. It is meant to help separate a storage or product problem from a true dosing problem, not to replace clinical judgment or a repeat lab draw ordered by a prescriber.

Step 1: Ask about heat exposure in the last 30 to 60 days. Has the packet or pump ever sat in a car, near a window with direct sun, above a heater, or in any space that regularly runs warmer than about 86°F? If yes, treat the current supply as suspect regardless of appearance, and consider a fresh fill before repeating labs.

Step 2: Ask about cold exposure or freezing. Was the product ever left somewhere that could have frozen it, such as an unheated car or a shipment left outside in winter? If yes, inspect for graininess, watery separation, or texture change. Any visible change means discard and replace; no visible change still warrants caution given the discussion above.

Step 3: Check the expiration date. If the product is expired, or within about 30 days of expiring, replace it before drawing a repeat testosterone level. Testing an expired or near-expired product's response is not a reliable way to judge whether the dose is right.

Step 4: Check appearance and smell at the point of use. Any color change, gritty texture, unusual odor, or watery separation is a discard trigger on its own, independent of storage history.

Step 5: Only after ruling out steps 1 through 4, treat a low level as a true dosing or absorption issue. If storage and expiration are both clean and the product looks and smells normal, an unexpectedly low serum testosterone level is more likely to reflect an application technique issue, a genuine absorption or dosing issue, or lab timing relative to application, and should be discussed with the prescribing clinician rather than managed by simply increasing the dose.

A "yes" answer at steps 1 through 4 should prompt getting a fresh, correctly stored product before drawing conclusions from a lab result. Escalating a dose based on a level drawn from compromised product risks overtreatment once a fresh, correctly stored product is resumed.

Practical storage checklist

• Keep packets or the pump in a dresser drawer or medicine cabinet away from bathroom steam and direct sunlight.
• Confirm the room stays reliably at or below 77°F, especially in summer.
• Never store in a car.
• Keep the pump cap tightly closed between uses.
• Check the expiration date at every refill.
• Discard anything with separation, graininess, color change, or unusual odor.
• Store away from open flame or smoking areas.
• Keep out of reach of children and pets.

When to seek urgent care

Signs of virilization in a child (early pubic hair, genital enlargement) or unusual signs in a partner after contact with a treated person's skin warrant prompt medical attention. Chest pain, shortness of breath, sudden severe headache, or leg swelling in a person using testosterone therapy warrant urgent evaluation, since testosterone therapy is associated with increased red blood cell production and, rarely, thrombotic events; this is a general safety consideration from testosterone therapy overall, not a storage-specific issue.

A note on sources used in this draft

This draft relies on FDA labeling, the FDA medication guide, FDA storage and disposal guidance, and the federal stability-testing regulation as its primary evidence for storage, flammability, disposal, and the boxed warning. Claims about specific trial results, guideline target numbers, and steady-state serum concentrations at individual doses were present in the original source material with citations that could not be independently verified against the actual papers, so they have been described in general terms here and flagged for confirmation against the current FDA label and primary literature before publication. A quotation attributed to a named trial investigator in the prior draft has been removed because it could not be verified as an accurate, attributable quotation from a checkable source.